Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2022

View Archived Issues

GPR30 is a therapeutic target in triple-negative inflammatory breast cancer

Small molecule inhibitors of natural killer group 2D identified at Janssen

Jazz and Werewolf announce global license and collaboration agreement to develop WTX-613

PX-478 prevents rise of glycemia and improves beta-cell function in models diabetes

Researchers in China find evidence in mice that bacteria in tumors help cancer cells metastasize

Novel HlyU inhibitor VM-17 attenuates the virulence of V. vulnificus

1st Bio Therapeutics presents new protein kinase inhibitors

Elastrin Therapeutics closes funding round to advance development of lead candidate

Seoul Techno Holdings identifies new compounds for cancer

Cadila Healthcare discloses new ACP1 inhibitors

Medshine Discovery patents AKR1C3 inhibitors

Soltego discloses new SIK inhibitors

New Fgf1a murine models of heart failure and metabolic syndrome developed

GPR171 agonism ameliorates chronic neuropathic and inflammatory pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...